Outcomes of Cerebral Embolic Protection for Bicuspid Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Replacement.
Humans
Transcatheter Aortic Valve Replacement
/ adverse effects
Bicuspid Aortic Valve Disease
/ complications
Constriction, Pathologic
Retrospective Studies
Hospital Mortality
Treatment Outcome
Aortic Valve Stenosis
/ complications
Heart Valve Diseases
/ surgery
Mitral Valve Stenosis
/ complications
Intracranial Embolism
/ epidemiology
Stroke
/ epidemiology
Aortic Valve
/ surgery
Risk Factors
National Inpatient Sample
aortic stenosis
bicuspid aortic valve
cerebral embolic protection
transcatheter aortic valve replacement
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
20 06 2023
20 06 2023
Historique:
medline:
21
6
2023
pubmed:
11
6
2023
entrez:
10
6
2023
Statut:
ppublish
Résumé
Background There was limited high-quality evidence that illuminated the efficiency of cerebral embolic protection (CEP) use during transcatheter aortic valve replacement (TAVR) for bicuspid aortic valve (BAV) stenosis. Methods and Results In this retrospective cohort study, patients with BAV stenosis undergoing TAVR with or without CEP were identified by querying the National Inpatient Sample database. The primary end point was any stroke during the hospitalization. The composite safety end point included any in-hospital death and stroke. We applied propensity score-matched analysis to minimize standardized mean differences of baseline variables and compare in-hospital outcomes. From July 2017 to December 2020, 4610 weighted hospitalizations with BAV stenosis undergoing TAVR were identified, of which 795 were treated with CEP. There was a significant increase in the CEP use rate for BAV stenosis (
Identifiants
pubmed: 37301750
doi: 10.1161/JAHA.122.028890
pmc: PMC10356028
doi:
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e028890Références
Am J Cardiol. 2021 Aug 1;152:169-170
pubmed: 34074489
JAMA. 2019 Jun 18;321(23):2306-2315
pubmed: 31211345
N Engl J Med. 2022 Oct 6;387(14):1253-1263
pubmed: 36121045
JACC Cardiovasc Interv. 2021 Mar 8;14(5):515-527
pubmed: 33663779
Am J Ther. 2021 Jun 25;28(5):e560-e572
pubmed: 34491954
JACC Cardiovasc Interv. 2020 Sep 28;13(18):2149-2155
pubmed: 32972578
Eur Heart J. 2021 Mar 7;42(10):1004-1015
pubmed: 33517376
JAMA Cardiol. 2022 Oct 1;7(10):1000-1008
pubmed: 36001335
JAMA. 2016 Aug 9;316(6):592-601
pubmed: 27532914
Eur Heart J. 2015 Aug 14;36(31):2070-2078
pubmed: 25990342
JAMA Intern Med. 2020 May 1;180(5):783-784
pubmed: 32091552
JACC Cardiovasc Interv. 2021 Oct 11;14(19):2144-2155
pubmed: 34620393
EuroIntervention. 2021 Feb 19;16(14):1141-1147
pubmed: 32894232
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
JACC Cardiovasc Interv. 2022 Mar 14;15(5):569-571
pubmed: 35272784
EuroIntervention. 2016 Jul 20;12(4):499-507
pubmed: 27436602
JAMA. 2019 Jun 11;321(22):2193-2202
pubmed: 31184741
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
JACC Cardiovasc Interv. 2019 Sep 23;12(18):1811-1822
pubmed: 31537280
JACC Cardiovasc Interv. 2018 Sep 10;11(17):1683-1693
pubmed: 30154060
J Am Coll Cardiol. 2017 Jan 31;69(4):367-377
pubmed: 27815101
EuroIntervention. 2022 May 15;18(1):23-32
pubmed: 35019840
J Am Coll Cardiol. 2020 Dec 1;76(22):2579-2590
pubmed: 33243378
Am J Cardiol. 2021 Aug 1;152:106-112
pubmed: 34147212